Free Newsletter
UK accepts J&J's money-back guarantee
It's official: the UK's National Health Service will start using Johnson & Johnson's Velcade, under an unprecedented money-back-guarantee program. Patients who respond to the drug will be fully funded. Patients who respond only minimally or not all all will be taken off Velcade, and J&J will refund the cost to NHS. The guarantee was the only way J&J could persuade the National Institute for Clinical Excellence--the drug gatekeepers for NHS--to reimburse for the drug at all.
- check out the CNN Money report
- read an analysis of the deal in The Telegraph
Related Articles:
J&J drug gets money-back guarantee. Report
Positive Velcade data fuels stock rise. Report
NHS fights expensive Alzheimer's drugs. Report
Metric: Biotech drugs fueling costs. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: